Novartis Experimental Cardiovascular Drug Fails Pivotal Study
Source Summary
Novartis announced Friday that an experimental cardiovascular drug failed in a pivotal study. The company described the failure as a major setback.
Why it matters
Failed pivotal studies can delay or prevent drug approvals and represent significant financial and strategic losses for pharmaceutical companies.
